Back to top

Optimistic Growth Potential for ANI Pharmaceuticals Despite Challenges in DME Treatment

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ANIP stock, giving a Buy rating yesterday. Faisal Khurshid has give...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ANI Pharmaceuticals, Inc. (ANIP)